Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.45Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -13.46%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements including regulatory approvals, strong study enrollments, and promising early results from clinical trials. Despite financial losses and coverage challenges for GLP-1 treatments, the advancements in the Revita and Rejuva platforms suggest a promising future for Fractyl's solutions in weight maintenance and metabolic health.Company Guidance
During Fractyl Health's fourth-quarter and full-year 2024 earnings call, CEO Dr. Harith Rajagopalan highlighted key metrics and milestones, focusing on the company's strategic advancements. In 2024, Fractyl completed its IPO, debuting on NASDAQ with the ticker symbol GUTS, and secured FDA IDE approval for a pivotal study on Revita's role in weight maintenance post GLP-1 drug discontinuation. The company initiated the REMAIN-1 pivotal study, which drew significant interest from patients and physicians. Fractyl also advanced its Rejuva gene therapy platform, with RJVA-001 and RJVA-002 candidates, garnering recognition at ADA's 84th Scientific Sessions. Financial metrics included a research and development expense of $20.3 million in Q4 2024, compared to $10.1 million in the same period in 2023, and a net loss of $25 million for the quarter. As of December 31, 2024, Fractyl held approximately $67.5 million in cash and cash equivalents, expected to fund operations into 2026. Looking ahead, 2025 is anticipated as a breakout year with pivotal data readouts and the first regulatory filings for the gene therapy platform.IPO and NASDAQ Debut
Fractyl Health completed its IPO, debuting on the NASDAQ under the ticker symbol GUTS, strengthening its financial position.
Regulatory Achievements
Secured FDA IDE approval for a pivotal study of Revita and earned FDA Breakthrough Device designation for weight maintenance after GLP-1 drug discontinuation.
Clinical Study Progress
Initiated the REMAIN-1 pivotal study with a strong patient enrollment, showing demand for an off-ramp to GLP-1 drugs. Over 189 patients enrolled across 13 clinical sites in six months.
Positive Early Patient Results
Initial results from REVEAL-1 showed a patient maintained weight loss during a challenging holiday period, suggesting Revita's potential effectiveness.
Rejuva Platform Advancements
Advanced Rejuva gene therapy platform, with preclinical data showing promise in preventing weight and glycemic rebound.
Financial Stability
Fractyl had $67.5 million in cash and cash equivalents, expected to fund operations through key clinical milestones into 2026.
---
GUTS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GUTS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $1.56 | $1.50 | -3.85% |
| Nov 12, 2024 | $2.43 | $2.37 | -2.47% |
| Aug 14, 2024 | $2.23 | $2.35 | +5.38% |
| May 13, 2024 | $6.10 | $6.62 | +8.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fractyl Health, Inc. (GUTS) report earnings?
Fractyl Health, Inc. (GUTS) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Fractyl Health, Inc. (GUTS) earnings time?
Fractyl Health, Inc. (GUTS) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GUTS EPS forecast?
GUTS EPS forecast for the fiscal quarter 2025 (Q1) is -0.45.
---